Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Bin Zhao ^1,^✉, Hong Zhao ^2,^✉, Jiaxin Zhao ^3,^✉

PMCID: PMC6329124 PMID: 30635053

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:101

Doi 10.1186/s40425-018-0421-z

Following publication of the original article [1], the authors reported an error in their listed affiliations.

In this Correction Dr. Jiaxin Zhao is related to two affiliations:

1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China.

3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.

The published apologizes for any inconvenience caused by this error.

Contributor Information

Bin Zhao, Email: doctorbinzhao@126.com.

Hong Zhao, Email: doctorhongzhao@126.com.

Jiaxin Zhao, Email: doctorzhaojiaxin@163.com.

1.Zhao, et al. Journal for ImmunoTherapy of Cancer. 2018;6(101). 10.1186/s40425-018-0421-z. [DOI] [PMC free article] [PubMed]